BBLG (Bone Biologics) Retained Earnings : $-85.02 Mil (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Bone Biologics Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Bone Biologics's retained earnings for the quarter that ended in Dec. 2024 was $-85.02 Mil.

Bone Biologics's quarterly retained earnings declined from Jun. 2024 ($-82.56 Mil) to Sep. 2024 ($-83.50 Mil) and declined from Sep. 2024 ($-83.50 Mil) to Dec. 2024 ($-85.02 Mil).

Bone Biologics's annual retained earnings declined from Dec. 2022 ($-71.96 Mil) to Dec. 2023 ($-80.91 Mil) and declined from Dec. 2023 ($-80.91 Mil) to Dec. 2024 ($-85.02 Mil).

Bone Biologics Retained Earnings Historical Data

The historical data trend for Bone Biologics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bone Biologics Retained Earnings Chart

Bone Biologics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Retained Earnings

Get a 7-Day Free Trial

-68.87

-70.48

-71.96

-80.91

-85.02

Bone Biologics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Retained Earnings	Get a 7-Day Free Trial															-80.91	-81.78	-82.56	-83.50	-85.02

Bone Biologics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Bone Biologics (NAS:BBLG) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Bone Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bone Biologics Corp (NAS:BBLG) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Burlington Woods Drive, Suite 100, Burlington, MA, USA, 01803

Website

https://www.bonebiologics.com

Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has applications in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.

Executives

Deina H Walsh	officer: Chief Financial Officer	175, MAY STREET, EDISON NJ 08837
Jeff Frelick	officer: Chief Operating Officer	1 FOX RUN LANE,, LEXINGTON MA 02420
Knight Insurance Company, Ltd	10 percent owner	4751 WILSHIRE BLVD.,, SUITE 111, LOS ANGELES CA 90010
Siddhesh Rajendra Angle	director	481 MONMOUTH ST, UNIT G,, JERSEY CITY NJ 07302
Erick Lucera	director	138 THISTLE ROAD, NORTH ANDOVER MA 08145
Don Hankey	director, 10 percent owner, officer: Chairman of the Board	4751 WILSHIRE BLVD., SUITE 110, LOS ANGELES CA 90010
Bret Hankey	director	4751 WILSHIRE BLVD. #110, LOS ANGELES CA 90010
Hankey Capital, Llc	10 percent owner	4751 WILSHIRE BLVD., #110, LOS ANGELES CA 90010
Don Hankey Trust	10 percent owner	4751 WILSHIRE BLVD., #110, LOS ANGELES CA 90010
Amir F Heshmatpour	10 percent owner	269 S. BEVERLY DRIVE, STE #1600, BEVERLY HILLS CA 90212
Musculoskeletal Transplant Foundation, Inc.	director	175 MAY STREET, SUITE 300, EDISON NJ 08837
Benjamin Wu	director	2740 LORAIN ROAD, SAN MARINO CA 91108
La Neve Stephen R.	director, officer: CEO and President	106 MCCOOL BLVD, WEST CHESTER PA 19380
George A Oram	director	12 EDGEMONT LANE, BEDMINSTER NJ 07921
Jim Delshad	director	132 S. MAPLE DR., BEVERLY HILLS CA 90212